NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Trial Profile

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Focus Therapeutic Use
  • Sponsors Nihon Pharmaceutical
  • Most Recent Events

    • 01 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top